The American Society of Clinical Oncology has released a research statement, “Measuring Ovarian Toxicity in Clinical Trials,” outlining new recommendations for appropriate assessment of ovarian toxicity in cancer clinical trials.
Researchers at Fox Chase Cancer Center demonstrated how amplification and rearrangement of a gene associated with leukemia, known as MLL, is directly controlled by epigenetic factors, providing needed insights into a new therapeutic opportunity.
City of Hope is initiating a multicenter clinical trial to evaluate the efficacy of robotic-assisted, single-incision mastectomies.
A team at Scripps Research and the Broad Institute of Harvard and MIT has discovered a new method to hone in on new drug targets most likely to impact multiple cancers.
The phase III MARIPOSA study met is primary endpoint resulting in statistically significant and clinically meaningful improvement in progression-free survival for Rybrevant (amivantamab-vmjw) plus lazertinib versus osimertinib in patients with EGFR-Mutated non-small cell lung cancer.
Findings from two subset analyses of the phase III MIRASOL trial (GOG 3045/ENGOT OV-55) evaluating the safety and efficacy of Elahere (mirvetuximab soravtansine-gynx) compared to chemotherapy in patients with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer demonstrate an overall survival and progression-free survival benefit.
Thoracic surgeons and researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine found that increasing numbers of patients undergoing cancer-removal lung surgery by “anatomic lung resections”—lobectomies or segmentectomies—are able to go home safely and without complications one day after the operation, thanks to growing rates of robot-assisted surgeries and improvements in patient-centered care protocols.
Salk Institute scientists discovered a relationship between killer T-cell exhaustion and the body’s sympathetic stress response, or “fight-or-flight,” in varying cancer types in mouse and human tissue samples.
Open Philanthropy has awarded $1.38 million to Philip Low, Purdue University’s Presidential Scholar for Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry in the College of Science, to validate a drug therapy using imatinib to treat malaria.
USC Norris Comprehensive Cancer Center has singled out mutations in 11 genes that are associated with aggressive forms of prostate cancer.
